The CLPB Knockout Raji Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population generated from human Raji B lymphocytes, targeting the CLPB gene to establish a loss-of-function model. This polyclonal population originates from bulk gene disruption without single-cell cloning, providing a heterogeneous knockout pool that recapitulates diverse mutational outcomes suitable for pooled functional genomics studies. The knockout disrupts endogenous CLPB expression, enabling researchers to interrogate the gene’s contribution to mitochondrial proteostasis and stress signaling in a B-lymphocyte background. The Raji host line, derived from Burkitt lymphoma, is a well-characterized model for adaptive immunity and antibody production, offering a relevant context for studying mitochondrial dysfunction in hematological malignancies.
The parental Raji cell line is a human Burkitt lymphoma-derived B lymphocyte line widely utilized in immunology and cancer research. These cells retain key features of mature B cells, including surface immunoglobulin expression and the capacity for robust antibody secretion, making them an important tool for investigating B-cell biology and lymphomagenesis. The lymphoma origin introduces intrinsic oncogenic signaling networks, such as c-MYC deregulation, which intersect with mitochondrial homeostasis and stress responses. This background enables integrated dissection of how CLPB loss influences both normal B-cell physiology and malignant transformation, providing a platform for comparative studies between healthy and neoplastic processes.
CLPB encodes a mitochondrial AAA+ chaperone that functions as a protein disaggregase, cooperating directly with mitochondrial HSP70 to resolubilize stress-induced protein aggregates and sustain mitochondrial proteostasis. The protein is activated by upstream mitochondrial stress signals and is transcriptionally regulated by ATF5 and heat shock factor 1 (HSF1) as part of the mitochondrial unfolded protein response (UPRmt). CLPB acts on aggregated mitochondrial matrix proteins and forms complexes with HSP70 and HSP60, while its activity intersects with the LONP1 protease. Mechanistically, loss of CLPB disrupts aggregate clearance, leading to the accumulation of damaged proteins that impair mitochondrial function. This triggers the integrated stress response through eIF2?? phosphorylation and downstream CHOP induction, sensitizing cells to proteotoxic and metabolic insults. The CLPB-HSP70 axis thus serves as a critical node in mitochondrial protein quality control and cellular stress resilience.
In the Raji lymphoma context, CLPB knockout provides a physiologically relevant model for examining how mitochondrial proteostasis defects influence B-cell physiology and oncogenesis. Disruption of CLPB is anticipated to compromise mitochondrial integrity, potentially altering ATP production, reactive oxygen species handling, and survival signaling in these rapidly proliferating lymphocytes. The integrated stress response activated by CLPB loss may intersect with MYC-driven growth and apoptotic pathways, offering insights into metabolic vulnerabilities of Burkitt lymphoma. Moreover, the model allows assessment of UPRmt signaling in antibody-producing cells, where high secretory demand places heavy reliance on mitochondrial function, linking CLPB deficiency to adaptive immune dysfunction and disease-associated phenotypes such as neutropenia and neurological abnormalities observed in 3-methylglutaconic aciduria type VII.
This polyclonal knockout product supports a wide range of experimental applications in mitochondrial biology and cancer research. Users can employ western blotting and RT-qPCR to monitor CLPB depletion and UPRmt target gene expression, respectively. Apoptosis assays and mitochondrial membrane potential measurements reveal sensitivity to mitochondrial toxins, while immunofluorescence and flow cytometry assess mitochondrial morphology and mass. Co-immunoprecipitation experiments validate CLPB-HSP70 interactions, and phospho-signaling analyses (e.g., eIF2?? phosphorylation) track stress pathway activation. The model is ideally suited for drug sensitivity screens, mechanistic studies of mitochondrial quality control in lymphoma, and investigations into neurodevelopmental contributions of CLPB dysfunction. For further technical details or ordering information, please contact Ascent Research.
